Press release in respect of audited (standalone and consolidated) financial results for the quarter and financial year ended 31 March 2026
SURAKSHA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Suraksha Diagnostic reported strong revenue growth with Total Income rising 22.5% YoY to ₹3,136 million in FY26. EBITDA grew 15.8% to ₹986 million, though EBITDA margin compressed from 33.8% to 31.8% due to investments in newly launched centres. PAT increased only 1.4% to ₹314 million, with Q4 PAT declining 14.1% YoY to ₹62 million. Test volumes surged 22% to 8.16 million tests, driven by network expansion adding 2 hubs, 11 spoke centres, and 4 PPP projects. Average revenue per test rose 15.6% in Q4 to ₹421. The company noted mature centres (>2 years old) maintain stable 36-37% EBITDA margins, while newer centres are in ramp-up phase.
Revenue growth is healthy but margin compression and minimal PAT growth may concern investors focused on profitability; the stock could face mixed reaction as expansion costs weigh on near-term earnings.